GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Feng Chi Biotech Corp (ROCO:6744) » Definitions » Cash Flow from Operations

Feng Chi Biotech (ROCO:6744) Cash Flow from Operations : NT$18.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Feng Chi Biotech Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the six months ended in Jun. 2024, Feng Chi Biotech's Net Income From Continuing Operations was NT$13.2 Mil. Its Depreciation, Depletion and Amortization was NT$4.2 Mil. Its Change In Working Capital was NT$-8.9 Mil. Its cash flow from deferred tax was NT$0.0 Mil. Its Cash from Discontinued Operating Activities was NT$0.0 Mil. Its Asset Impairment Charge was NT$0.0 Mil. Its Stock Based Compensation was NT$0.0 Mil. And its Cash Flow from Others was NT$-2.3 Mil. In all, Feng Chi Biotech's Cash Flow from Operations for the six months ended in Jun. 2024 was NT$6.3 Mil.


Feng Chi Biotech Cash Flow from Operations Historical Data

The historical data trend for Feng Chi Biotech's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Feng Chi Biotech Cash Flow from Operations Chart

Feng Chi Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial 23.61 39.29 32.93 28.49 15.42

Feng Chi Biotech Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.73 31.22 3.12 12.30 6.29

Feng Chi Biotech Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Feng Chi Biotech's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

Feng Chi Biotech's Cash Flow from Operations for the quarter that ended in Jun. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$18.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Feng Chi Biotech  (ROCO:6744) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Feng Chi Biotech's net income from continuing operations for the six months ended in Jun. 2024 was NT$13.2 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Feng Chi Biotech's depreciation, depletion and amortization for the six months ended in Jun. 2024 was NT$4.2 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Feng Chi Biotech's change in working capital for the six months ended in Jun. 2024 was NT$-8.9 Mil. It means Feng Chi Biotech's working capital declined by NT$8.9 Mil from Dec. 2023 to Jun. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Feng Chi Biotech's cash flow from deferred tax for the six months ended in Jun. 2024 was NT$0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Feng Chi Biotech's cash from discontinued operating Activities for the six months ended in Jun. 2024 was NT$0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Feng Chi Biotech's asset impairment charge for the six months ended in Jun. 2024 was NT$0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Feng Chi Biotech's stock based compensation for the six months ended in Jun. 2024 was NT$0.0 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Feng Chi Biotech's cash flow from others for the six months ended in Jun. 2024 was NT$-2.3 Mil.


Feng Chi Biotech Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Feng Chi Biotech's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Feng Chi Biotech Business Description

Traded in Other Exchanges
N/A
Address
No. 5, Shaoxing North Street, 5th Floor-1, Zhongzheng District, Taipei City, TWN, 100
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.

Feng Chi Biotech Headlines

No Headlines